Want to see HK:2453 full AI Analyst Report?
2453 Stock Chart & Stats
HK$1.83
-HK$0.24(-2.76%)
At close: 4:00 PM EST
HK$1.83
-HK$0.24(-2.76%)
Day’s Range― - ―
52-Week RangeHK$0.67 - HK$7.49
Previous CloseN/A
Volume2.50M
Average Volume (3M)590.21K
Market Cap
HK$587.75M
Enterprise ValueHK$3.37B
Total Cash (Recent Filing)HK$319.01M
Total Debt (Recent Filing)HK$3.09B
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding313,874,630
10 Day Avg. Volume440,520
30 Day Avg. Volume590,206
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.62
Price to Sales (P/S)2.55
P/FCF Ratio-4.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Rebound & Margin RecoveryA 21% revenue rebound in 2025 with gross margin turning positive (~7%) indicates demand recovery and improved unit economics. If sustained, this provides a durable foundation for scaling operations, narrowing losses, and supporting investment in service improvements over the next several quarters.
Improving Balance Sheet Equity & Lower LeverageReduction in leverage from ~1.95x to ~1.7x and rising positive equity improves financial flexibility versus the prior year. This structural improvement lowers refinancing strain and gives management more runway to execute operational fixes or invest selectively without immediate crisis-driven funding needs.
Proven Ability To Generate Operating Cash HistoricallyPrior positive operating cash flow in 2023 demonstrates the underlying business can convert revenue to cash under different operating conditions. That historical capability suggests management can restore cash generation with consistent revenue and cost control, reducing long-term reliance on external financing.
Bears Say
Deep Operating And Net LossesVery large operating and net losses indicate the core service economics remain unprofitable at current scale. Persisting such wide negative margins over multiple periods erodes capital, limits reinvestment capacity, and implies structural cost or pricing issues that must be resolved for sustainable profitability.
Negative Operating & Free Cash FlowConsecutive years of negative operating cash flow and materially negative free cash flow in 2025 create persistent funding pressure. This reduces strategic optionality, increases likelihood of external capital needs, and raises the risk of dilution or costly financing if improvement in cash conversion is not achieved.
Elevated Leverage With Negative ROEHigh leverage combined with negative returns on equity signals inefficient use of capital and constrained financial flexibility. Creditors may demand tighter terms and interest burdens may amplify losses, making it harder to fund growth or absorb shocks until returns turn positive.
Concord Healthcare Group Co., Ltd. Class H News
2453 FAQ
What was Concord Healthcare Group Co., Ltd. Class H’s price range in the past 12 months?
Concord Healthcare Group Co., Ltd. Class H lowest stock price was HK$0.67 and its highest was HK$7.49 in the past 12 months.
What is Concord Healthcare Group Co., Ltd. Class H’s market cap?
Concord Healthcare Group Co., Ltd. Class H’s market cap is HK$587.75M.
When is Concord Healthcare Group Co., Ltd. Class H’s upcoming earnings report date?
Concord Healthcare Group Co., Ltd. Class H’s upcoming earnings report date is Aug 27, 2026 which is in 53 days.
How were Concord Healthcare Group Co., Ltd. Class H’s earnings last quarter?
Concord Healthcare Group Co., Ltd. Class H released its earnings results on Mar 26, 2026. The company reported -HK$0.112 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.112.
Is Concord Healthcare Group Co., Ltd. Class H overvalued?
According to Wall Street analysts Concord Healthcare Group Co., Ltd. Class H’s price is currently Overvalued.
Does Concord Healthcare Group Co., Ltd. Class H pay dividends?
Concord Healthcare Group Co., Ltd. Class H does not currently pay dividends.
What is Concord Healthcare Group Co., Ltd. Class H’s EPS estimate?
Concord Healthcare Group Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Concord Healthcare Group Co., Ltd. Class H have?
Concord Healthcare Group Co., Ltd. Class H has 313,874,630 shares outstanding.
What happened to Concord Healthcare Group Co., Ltd. Class H’s price movement after its last earnings report?
Concord Healthcare Group Co., Ltd. Class H reported an EPS of -HK$0.112 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.167%.
Which hedge fund is a major shareholder of Concord Healthcare Group Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2453
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Concord Healthcare Group Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-87.59%
12-Months-Change
Fundamentals
Return on Equity
-15.15%
Trailing 12-Months
Asset Growth
2.55%
Trailing 12-Months
Company Description
Concord Healthcare Group Co., Ltd. Class H
Concord Healthcare Group Co., Ltd. is dedicated to providing comprehensive cancer treatment services for patients and healthcare institutions throughout China. Its operations extend beyond direct care to include the distribution and installation of medical hardware and software, along with offering management and technical assistance, and providing equipment via operating leases. The company was founded in 2008 and is headquartered in Beijing, China. It functions as a subsidiary of Shanghai Medstar Financial Leasing Company.
Technical Analysis
C-MER Eye Care Holdings Limited
―
Hospital Corporation of China Ltd
―
Town Health International Medical Group Ltd.
―
Hygeia Healthcare Holdings Co., Ltd.
―
Arrail Group Ltd.
―